跳至主要内容
临床试验/IRCT201206279801N3
IRCT201206279801N3已完成3 期

Comparison of efficacy and adverse effects of filgrastim produced by Samen pharmaceutical company and neupogen as a standard drug in Breast Cancer Patients

Samen Pharmaceutical Company0 个研究点目标入组 168 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
168

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
Female

入选标准

  • Age>18 yr; Diagnosis of locally advanced breast cancer; WHO Performance Status less than or equal of 2; Absence of neutropenia (ANC <1500/mm3) before starting chemotherapy; Completing the Consent form.
  • Exclusion criteria: History of hypersensitivity reaction to biologic drugs; Existence of renal failure ; Existence of hepatic failure ; Coadministration of neutropoietic drugs; Existence of cardiac arrythmia.

排除标准

  • 未提供

研究者

发起方
Samen Pharmaceutical Company

相似试验